Insulin

Insulin
Name	Insulin
System	Endocrine

Insulin is a peptide hormone produced by the pancreatic islets that plays a central role in regulating carbohydrate, lipid, and protein metabolism. It acts as a key anabolic signal coordinating cellular uptake of glucose and synthesis of glycogen, triglycerides, and protein across multiple tissues. Dysregulation of insulin production or action underlies major medical conditions affecting global public health.

Structure and biosynthesis

Insulin is synthesized as a single-chain precursor, preproinsulin, that undergoes cotranslational and posttranslational processing to yield the mature disulfide-linked A and B chains. Preproinsulin translation occurs in pancreatic β cells of the islets of Langerhans under control of transcription factors such as PDX1, MAFA, and NEUROD1 and the peptide is routed through the endoplasmic reticulum and Golgi apparatus for conversion to proinsulin and cleavage by PCSK1 and PCSK2 convertases. Granule storage and regulated exocytosis involve proteins and pathways studied in models including Saccharomyces cerevisiae, Mus musculus, and Rattus norvegicus and draw on insights from work in Harvard University, Massachusetts Institute of Technology, and the Max Planck Society. The primary sequence and three-dimensional fold were elucidated using techniques developed by researchers at institutions such as Cambridge University and ETH Zurich, and disulfide pairing between cysteine residues stabilizes the native conformation required for receptor binding.

Physiological functions

Insulin promotes glucose uptake in insulin-sensitive tissues, notably skeletal muscle and adipose tissue, by stimulating translocation of GLUT4-containing vesicles via signaling cascades engaging phosphoinositide 3-kinase and AKT. It enhances hepatic glycogen synthesis while suppressing hepatic gluconeogenesis regulated by factors including FOXO1 and C/EBPα, and it stimulates lipogenesis in adipose and hepatic tissue mediated by SREBP1c and ChREBP. In the central nervous system, insulin modulates neuronal metabolism and synaptic plasticity with implications studied by groups at University College London and Stanford University. Systemic effects intersect with endocrine axes involving the hypothalamus, pituitary gland, and adrenal medulla, and with peripheral organs such as the kidney and heart.

Regulation of secretion and signaling

Glucose-stimulated insulin secretion is initiated when elevated blood glucose increases ATP/ADP ratio in β cells, closes ATP-sensitive K+ channels (formed by KCNJ11 and ABCC8 subunits), depolarizes the membrane, and opens voltage-gated Ca2+ channels to trigger exocytosis. Incretin hormones such as glucagon-like peptide-1 and gastric inhibitory polypeptide potentiate secretion via G protein–coupled receptors, while autonomic inputs from the vagus nerve and sympathetic fibers modulate release through adrenergic receptors. Insulin signaling through the insulin receptor activates downstream effectors, including insulin receptor substrates (IRS) and the RAS–MAPK pathway, integrating mitogenic and metabolic responses; dysregulation of these pathways has been explored by consortia at NIH, Wellcome Trust, and the European Molecular Biology Laboratory.

Clinical significance and disorders

Deficient insulin production causes hyperglycemia and diabetes mellitus; autoimmune destruction of β cells characterizes Type 1 diabetes mellitus, whereas insulin resistance with relative insulin deficiency typifies Type 2 diabetes mellitus. Mutations in genes such as INS, KCNJ11, and HNF1A produce monogenic forms including neonatal diabetes and maturity-onset diabetes of the young studied at centers like Joslin Diabetes Center and Karolinska Institute. Excess insulin or exogenous overadministration can provoke hypoglycemia with neurologic sequelae managed in emergency settings in hospitals such as Mayo Clinic and Cleveland Clinic. Chronic complications of dysglycemia involve microvascular disease (retinopathy, nephropathy, neuropathy) and macrovascular disease (ischemic heart disease, stroke) addressed in trials coordinated by groups including UK Prospective Diabetes Study and DCCT/EDIC investigators.

Therapeutic uses and pharmacology

Insulin preparations span rapid-, short-, intermediate-, and long-acting formulations engineered by pharmaceutical companies like Eli Lilly and Company, Novo Nordisk, and Sanofi to optimize pharmacokinetics for basal-bolus regimens and continuous subcutaneous infusion via insulin pumps. Biosynthetic human insulin and analogues were developed using recombinant DNA techniques pioneered at institutions such as Genentech and licensed following regulatory review by agencies including the Food and Drug Administration and the European Medicines Agency. Therapeutic strategies integrate glucose monitoring technologies (including continuous glucose monitors developed by Dexcom and Medtronic), closed-loop artificial pancreas systems evaluated at centers like Sheffield Teaching Hospitals and University of Virginia, and adjunctive agents such as metformin and GLP-1 receptor agonists from trials run by collaborations including International Diabetes Federation initiatives.

History and discovery

The discovery and therapeutic isolation of insulin as a life-saving treatment for diabetes were achieved in the early 20th century by investigators across Canada and Europe, with seminal work conducted at University of Toronto and clinical leadership from figures affiliated with Toronto General Hospital. The elucidation of insulin’s chemical structure and synthesis involved Nobel-recognized contributions and subsequent structural studies performed in laboratories at University of Cambridge and Rockefeller University. Translational and commercial development engaged pharmaceutical enterprises and regulatory bodies such as Health Canada and led to widespread clinical adoption that transformed diabetes care throughout the 20th century.

Category:Hormones Category:Peptide hormones Category:Endocrinology